Recipharm and Adroit Science form Collaboration to Expand Service Offering
Recipharm and Adroit Science have announce the formation of a new strategic collaboration. Adroit Science will support Recipharm’s pharmaceutical development with high quality solid state characterisation services. By combining expertise in formulation development, API development, chemical analysis and solid state characterisation, both the speed and cost of development can be reduced whilst, at the same time, quality is improved.
“I am very excited about this collaboration”, says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm. “With the addition of development services from Adroit, we will have a very competitive offering, which will help our customers to progress their projects in a highly efficient way. Adroit Science AB has fast established itself as one of the leading providers of solid state characterisation services in Northern Europe. Indeed, we can offer an even better service to our customers through this collaboration, including complete development from molecule to product.”
“Adroit Science and Recipharm have already cooperated in a number of successful projects, and this formal partnership marks the logical next step in the mutual development of our strategic relationship. We are delighted to join forces with a leading CDMO like Recipharm and predict that this will bring new opportunities in worldwide customer support” remarked Hans Gredeby, CEO of Adroit Science.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.